PDS-0301

N/A

Report date: 2023/10/13 16:51:01

Base Information

Drug NamePDS-0301
Drug Alias NameNHS-IL12/MSB0010360NHS-IL12 humanNHS-huIL12NHS-muIL12NHS-IL 12 +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-12 stimulants
TargetsInterleukin-12
Therapy Area/IndicationsMetastatic breast cancerUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[26] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEmd Serono IncMerck SeronoNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesPds Biotechnology CorpNational Cancer Institute
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[23] 
Inactive IndicationsMetastatic breast cancerPancreatic NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A